Table 3 Characteristics of UTIs

Type of infection

• Community-acquired, n (%)

20 (64.5)

• Hospital-acquired, n (%)

11 (35.5)

Catheter-associated urinary tract infection, n (%)

10 (32.3)

Duration of retained Foley catheter since admission (days), median (IQR)

12 (5, 28.75)

Time to acquire urinary tract infection (days), median (IQR)

2 (1, 7)

Symptoms

• Fever, n (%)

30 (96.8)

• Turbid urine, n (%)

14 (45.2)

• Urinary retention, n (%)

13 (41.9)

• Dysuria, n (%)

6 (19.4)

• Urinary incontinence, n (%)

2 (6.5)

• Gross hematuria, n (%)

1 (3.2)

SIRS criteria (points), median (IQR)

3 (2, 4)

qSOFA (points), median (IQR)

1 (1, 2)

Secondary bacteremia, n (%)

2 (6.5)

Pathogens

• Escherichia coli, n (%)

13 (41.9)

• Klebsiella pneumoniae, n (%)

5 (16.1)

• Enterococcus faecalis, n (%)

4 (12.9)

• Acinetobacter baumannii, n (%)

3 (9.7)

Antibiotics susceptible to Escherichia coli (N = 13)

• Amoxicillin/clavulanic acid, n (%)

11 (84.6)

• Ceftriaxone, n (%)

11 (84.6)

• Ceftazidime, n (%)

11 (84.6)

• Cefepime, n (%)

11 (84.6)

• Gentamicin, n (%)

8 (61.5)

• Amikacin, n (%)

13 (100)

• Ciprofloxacin, n (%)

5 (38.5)

• Trimethoprim/sulfamethoxazole, n (%)

9 (69.6)

• Piperacillin/tazobactam, n (%)

12 (92.3)

• Ertapenem, n (%)

13 (100)

• Meropenem, n (%)

13 (100)

Treatment (N = 30)

Monotherapy, n (%)

23 (76.7)

• Ceftriaxone, n (%)

11 (36.7)

• Ceftazidime, n (%)

5 (16.7)

• Piperacillin/tazobactam, n (%)

7 (23.3)

Combination therapy, n (%)

7 (23.3)